- Home
- KRUS vs EOLS Comparison
KRUS vs EOLS Comparison
Compare KRUS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRUS
- EOLS
- Stock Information
- Founded
- KRUS 2008
- EOLS 2012
- Country
- KRUS United States
- EOLS United States
- Employees
- KRUS N/A
- EOLS N/A
- Industry
- KRUS Restaurants
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- KRUS Consumer Discretionary
- EOLS Health Care
- Exchange
- KRUS Nasdaq
- EOLS Nasdaq
- Market Cap
- KRUS 915.2M
- EOLS 787.7M
- IPO Year
- KRUS 2019
- EOLS 2018
- Fundamental
- Price
- KRUS $95.54
- EOLS $13.04
- Analyst Decision
- KRUS Buy
- EOLS Strong Buy
- Analyst Count
- KRUS 8
- EOLS 6
- Target Price
- KRUS $84.88
- EOLS $22.60
- AVG Volume (30 Days)
- KRUS 211.9K
- EOLS 676.4K
- Earning Date
- KRUS 01-02-2025
- EOLS 11-06-2024
- Dividend Yield
- KRUS N/A
- EOLS N/A
- EPS Growth
- KRUS N/A
- EOLS N/A
- EPS
- KRUS N/A
- EOLS N/A
- Revenue
- KRUS $237,860,000.00
- EOLS $248,326,000.00
- Revenue This Year
- KRUS $20.49
- EOLS $33.57
- Revenue Next Year
- KRUS $20.52
- EOLS $32.91
- P/E Ratio
- KRUS N/A
- EOLS N/A
- Revenue Growth
- KRUS 26.91
- EOLS 34.42
- 52 Week Low
- KRUS $48.66
- EOLS $9.29
- 52 Week High
- KRUS $122.81
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- KRUS 55.65
- EOLS 38.46
- Support Level
- KRUS $82.72
- EOLS $11.88
- Resistance Level
- KRUS $95.44
- EOLS $12.67
- Average True Range (ATR)
- KRUS 6.35
- EOLS 0.74
- MACD
- KRUS -1.07
- EOLS -0.16
- Stochastic Oscillator
- KRUS 55.07
- EOLS 27.51
About KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a Japanese restaurant company. It operates revolving sushi chain restaurants in the United States. It provides access to the revolving and express conveyor belts, on-demand ordering screen, plate slot, and the Bikkura-Pon rewards machine. The company offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, Salmon, among others. Geographically, it derives revenue from the United States of America.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.